Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 41.4% in July

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totaling 11,313 shares, a drop of 41.4% from the July 15th total of 19,290 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 16,846 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Price Performance

XBIO opened at $3.25 on Wednesday. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93. The company’s 50-day moving average is $2.89 and its 200 day moving average is $2.85. The firm has a market capitalization of $7.44 million, a PE ratio of -2.80 and a beta of 2.10.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The company had revenue of $0.66 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.